Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism

[1]  G. Du,et al.  Therapeutic effects of baicalein on rotenone-induced Parkinson’s disease through protecting mitochondrial function and biogenesis , 2017, Scientific Reports.

[2]  G. Martino,et al.  IL4 induces IL6-producing M2 macrophages associated to inhibition of neuroinflammation in vitro and in vivo , 2016, Journal of Neuroinflammation.

[3]  Stanley Fahn,et al.  Levodopa therapy for Parkinson disease , 2016, Neurology.

[4]  Bin Liu,et al.  Autophagy-related protein expression in the substantia nigra and eldepryl intervention in rat models of Parkinson׳s disease , 2015, Brain Research.

[5]  X. Qin,et al.  Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson's disease: A microarray study , 2015, Pharmacology Biochemistry and Behavior.

[6]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[7]  J. Yeh,et al.  Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways , 2014, BMC Complementary and Alternative Medicine.

[8]  Xueli Li,et al.  Baicalein ameliorated the upregulation of striatal glutamatergic transmission in the mice model of Parkinson's disease , 2014, Brain Research Bulletin.

[9]  Yujeong Lee,et al.  Baicalein attenuates astroglial activation in the 1‐methyl‐4‐phenyl‐1,2,3,4‐tetrahydropyridine‐induced Parkinson's disease model by downregulating the activations of nuclear factor‐κB, ERK, and JNK , 2014, Journal of neuroscience research.

[10]  Effects of intravenous human umbilical cord blood CD34+ stem cell therapy versus levodopa in experimentally induced Parkinsonism in mice , 2013, Archives of medical science : AMS.

[11]  T. Manivasagam,et al.  Melatonin synergizes with low doses of L‐DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism , 2013, Journal of pineal research.

[12]  R. Benecke,et al.  Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease , 2013, Journal of neuroscience research.

[13]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[14]  M. Asanuma,et al.  Protective effects of baicalein against excess L-DOPA-induced dopamine quinone neurotoxicity , 2011, Neurological research.

[15]  S. Duty,et al.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease , 2011, British journal of pharmacology.

[16]  G. Du,et al.  Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice , 2011, Pharmacology Biochemistry and Behavior.

[17]  G. Du,et al.  Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro , 2009, Pharmacology Biochemistry and Behavior.

[18]  Ikuko Miyazaki,et al.  Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease , 2009, Neurotoxicity Research.

[19]  S. Przedborski,et al.  Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.

[20]  T. Archer,et al.  Synergistic interactions between NMDA-antagonists and L-Dopa on activity in MPTP-treated mice , 2006, Journal of Neural Transmission / General Section JNT.

[21]  Andreas Hald,et al.  Oxidative stress and inflammation in Parkinson's disease: is there a causal link? , 2005, Experimental Neurology.

[22]  Heh-In Im,et al.  Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice. , 2005, Journal of pharmacological sciences.

[23]  T. Archer,et al.  Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice , 2005, Journal of Neural Transmission / General Section JNT.

[24]  Z. Pei,et al.  Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons , 2005, Journal of Neural Transmission.

[25]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[26]  Joseph Jankovic,et al.  Treatment options for Parkinson's disease. , 2002 .

[27]  F. Nicoletti,et al.  Time-course and dose–response study on the effects of chronic l-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity , 2000, Brain Research.

[28]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[29]  Y. Michotte,et al.  The Significance of Homovanillic Acid and 3,4‐Dihydroxyphenylacetic Acid Concentrations in Human Lumbar Cerebrospinal Fluid , 1987, Journal of neurochemistry.